Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;14(2):121–130. doi: 10.1111/j.1750-3639.2004.tb00044.x

Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival

Jörg Felsberg 1,7, Angelika Erkwoh 2, Michael C Sabel 3, Lutz Kirsch 4, Rolf Fimmers 5, Britta Blaschke 1, Uwe Schlegel 6, Johannes Schramm 2, Otmar D Wiestler 7, Guido Reifenberger 1,✉
PMCID: PMC8095961  PMID: 15193024

Abstract

Loss of heterozygosity (LOH) on the chromosome arms 1p and 19q is frequent in oligodendroglial tumors and has been correlated with chemosensitivity and good prognosis in anaplastic oligodendrogliomas. The oligodendroglioma‐associated tumor suppressor genes on 1p and 19q are as yet unknown. To narrow down candidate regions on 1p, we investigated oligodendroglial tumors from 89 patients for LOH at up to 30 polymorphic loci on 1p. In addition, all tumors were studied for LOH at 7 loci on 19q. Combined LOH on 1p and 19q was detected in 20 (83%) of 24 oligodendrogliomas, 15 (63%) of 24 anaplastic oligodendrogliomas, 10 (56%) of 18 oligoastrocytomas, and 12 (52%) of 23 anaplastic oligoastrocytomas. Five tumors demonstrated partial deletions on 1p, which allowed to define 3 distinct candidate regions at 1 p36.31 ‐pter distal to D1S2633, 1p36.22‐p36.31 between D1S489 and D1S2642, and 1p34.2‐p36.1 between D1S2743 and D1S482, respectively. No partial deletions were detected on 19q. Combined LOH on 1p and 19q was associated with prolonged time to progression (TTP), longer overall survival (OS), and a higher 5‐year survival rate. Depending on the presence or absence of combined LOH on 1p and 19q, patients with anaplastic oligodendroglial tumors treated with adjuvant radio‐ and/or chemotherapy showed a median TTP of 86 months versus 39 months, a median OS of 91 months versus 46 months, and a 5‐year survival rate of 80% versus 36%, respectively. Similarly, LOH on 1p and 19q was associated with longer survival in patients with low‐grade oligodendroglial tumors (TTP: 57 months versus 47 months; OS: 172 months versus 105 months; 5‐year survival rate: 92% versus 70%). Thus, our results refine the location of putative oligodendroglioma suppressor genes on 1p and support the significance of LOH on 1p and 19q as a favorable prognostic marker.

Full Text

The Full Text of this article is available as a PDF (603.3 KB).

REFERENCES

  • 1. Alonso ME, Bello MJ, Gonzalez‐Gomez P, Lomas J, Arjona D, de Campos JM, Kusak ME, Sarasa JL, Isla A, Rey JA (2001) Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer 85:204–208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Bauman GS, Cairncross JG (2001) Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo‐astrocytomas. Semin Radiat Oncol 11:170–180. [DOI] [PubMed] [Google Scholar]
  • 3. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Rad Oncol Biol Phys 48: 825–830xc. [DOI] [PubMed] [Google Scholar]
  • 4. Bello MJ, de Campos JM, Vaquero J, Ruiz‐Barnes P, Kusak ME, Sarasa JL, Rey JA (2000) hRAD54 gene and 1p high‐resolution deletion‐mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet 116:142–147. [DOI] [PubMed] [Google Scholar]
  • 5. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207–210. [DOI] [PubMed] [Google Scholar]
  • 6. Boström J, Muhlbauer A, Reifenberger G (1997) Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol (Berl) 94:479–485. [DOI] [PubMed] [Google Scholar]
  • 7. Cairncross JG, Ueki K, Zlatescu C Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. [DOI] [PubMed] [Google Scholar]
  • 8. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273. [DOI] [PubMed] [Google Scholar]
  • 9. Chinot O (2001) Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28 (4 Suppl 13):13–18. [DOI] [PubMed] [Google Scholar]
  • 10. Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95:493–504. [DOI] [PubMed] [Google Scholar]
  • 11. Dong S, Pang JC, Hu J, Zhou LF, Ng HK (2002) Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 98:370–375. [DOI] [PubMed] [Google Scholar]
  • 12. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pernicone P, Altermatt H (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262. [DOI] [PubMed] [Google Scholar]
  • 13. Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN (2002) Transcript map of the 3.7‐Mb D19S112‐D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 62:4100–4108. [PubMed] [Google Scholar]
  • 14. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K (2003) Correlation between genetic alteration and long‐term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97: 2254–2261. [DOI] [PubMed] [Google Scholar]
  • 15. Hoang‐Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre JY, Poirier J, Broet P, Sanson M (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278–1281. [DOI] [PubMed] [Google Scholar]
  • 16. Husemann K, Wolter M, Büschges R, Bostrom J, Sabel M, Reifenberger G (1999) Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene at 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 58:1041–1050. [DOI] [PubMed] [Google Scholar]
  • 17. Ichimura K, Schmidt EE, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the CDKN2A (p16 INK4A MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065–1072. [PubMed] [Google Scholar]
  • 18. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer‐Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845. [PubMed] [Google Scholar]
  • 19. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, Ohira M, Yamaura A, Osato K, Sakiyama S, Nakagawara A (2002) Identification of the small interstitial deletion at chromosome band 1p34‐p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 35:170–175. [DOI] [PubMed] [Google Scholar]
  • 20. Jenkins RB, Curran W, Scott CB, Cairncross G (2001) Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 24: 506–508. [DOI] [PubMed] [Google Scholar]
  • 21. Kim L, Hochberg FH, Thornton AF, Harsh GR 4th, Patel H, Finkelstein D, Louis DN (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85: 602–607. [DOI] [PubMed] [Google Scholar]
  • 22. Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 58: 237–253. [DOI] [PubMed] [Google Scholar]
  • 23. Kros JM, Pieterman H, van Eden CG, Avezaat CJ (1994) Oligodendroglioma: the Rotterdam‐Dijkzigt experience. Neurosurgery 34:959–966. [DOI] [PubMed] [Google Scholar]
  • 24. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W (1998) Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1p‐arm deletions. Genomics 51: 359–363. [DOI] [PubMed] [Google Scholar]
  • 25. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Olson JD, Riedel E, DeAngelis LM (2000) Long‐term outcome of low‐grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448. [DOI] [PubMed] [Google Scholar]
  • 27. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:A1–9. [DOI] [PubMed] [Google Scholar]
  • 28. Perry JR, Louis DN, Cairncross JG (1999) Current treatment of oligodendrogliomas. Arch Neurol 56: 434–436. [DOI] [PubMed] [Google Scholar]
  • 29. Pohl U, Cairncross JG, Louis DN (1999) Homozygous deletions of the CDKN2C/p18 INK4c gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 9:639–643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligodendroglial tumours and mixed gliomas. In: Kleihues P, Cavenee WK, editors. Tumours of the Nervous System: Pathology and Genetics. World Health Organization Classification of Tumours Lyon , IARC Press, pp 55–70. [Google Scholar]
  • 31. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol 62:111–126. [DOI] [PubMed] [Google Scholar]
  • 32. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190. [PMC free article] [PubMed] [Google Scholar]
  • 33. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. 2nd edition USA : Cold Spring Harbor Laboratory Press, pp 9.17–9.19. [Google Scholar]
  • 34. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low‐ versus high‐dose radiation therapy in adults with supratentorial low‐grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267–2276. [DOI] [PubMed] [Google Scholar]
  • 35. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428–434. [DOI] [PubMed] [Google Scholar]
  • 36. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH (1994) Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 34: 577–582. [DOI] [PubMed] [Google Scholar]
  • 37. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152. [DOI] [PubMed] [Google Scholar]
  • 38. Smith JS, Jenkins RB (2000) Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5:D213–231. [DOI] [PubMed] [Google Scholar]
  • 39. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636–645. [DOI] [PubMed] [Google Scholar]
  • 40. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97: 1276–1284. [DOI] [PubMed] [Google Scholar]
  • 41. Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P, Ohgaki H (2002) Methylation of the p73 gene in gliomas. Acta Neuropathol (Berl) 104: 357–362. [DOI] [PubMed] [Google Scholar]
  • 42. Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, Hudson TJ, Black PM (1998) Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 21:207–216. [DOI] [PubMed] [Google Scholar]
  • 43. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715. [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES